Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, with a primary emphasis on acid-related disorders. The company’s core mission is to address limitations of existing proton pump inhibitor (PPI) therapies by introducing differentiated acid-suppression medicines with faster onset and more consistent control. Phathom operates within the biopharmaceuticals and specialty therapeutics industry and primarily serves gastroenterologists, hospitals, and patients with chronic GI conditions.
Phathom was founded in 2018 and became a publicly traded company in 2019. Its strategy has centered on advancing vonoprazan, a potassium-competitive acid blocker (P-CAB) licensed from Takeda Pharmaceutical Company, for multiple U.S. indications. The company’s positioning is based on vonoprazan’s differentiated mechanism of action compared to traditional PPIs, offering rapid and sustained acid suppression. Over time, Phathom has evolved from a development-stage company into a commercial-stage organization following U.S. regulatory approvals.
Business Operations
Phathom’s business operations are organized around the development, regulatory approval, and commercialization of prescription GI therapeutics, with revenue generation driven primarily by product sales in the United States. Its lead and currently marketed products include Voquezna, Voquezna Triple Pak, and Voquezna Dual Pak, which are approved for the treatment of erosive gastroesophageal reflux disease (GERD) and Helicobacter pylori (H. pylori) infection. Commercial activities include physician engagement, payer access efforts, and patient support programs.
The company does not operate manufacturing facilities and instead relies on third-party contract manufacturers for drug production and packaging. Phathom’s key asset is its exclusive U.S. license to vonoprazan, while international rights largely remain with Takeda Pharmaceutical Company. Operations are primarily domestic, with no material international commercial sales reported to date.
Strategic Position & Investments
Phathom’s strategic direction is focused on expanding adoption of vonoprazan-based therapies across approved indications and pursuing additional lifecycle opportunities within acid-related GI diseases. Growth initiatives include increasing market penetration in GERD and H. pylori treatment, expanding payer coverage, and generating post-approval clinical data to support broader physician adoption.
The company’s most significant strategic investment is its licensing agreement with Takeda Pharmaceutical Company, which underpins its entire product portfolio. Phathom has not announced major acquisitions and does not operate a diversified subsidiary structure, reflecting a concentrated strategy centered on a single therapeutic platform. Its involvement in P-CAB technology positions it within an emerging segment of acid-suppression therapies distinct from legacy PPIs.
Geographic Footprint
Phathom Pharmaceuticals is headquartered in the United States, with its principal executive offices in New Jersey. The company’s commercial footprint is currently concentrated in North America, where it conducts all product sales, regulatory activities, and commercial operations.
While Phathom has no direct operational presence outside the U.S., its strategic and clinical footprint is indirectly global through its reliance on international manufacturing partners and its licensing relationship with Takeda Pharmaceutical Company, which markets vonoprazan in Asia and other international regions. At present, international expansion is not a material contributor to revenue.
Leadership & Governance
Phathom is led by an executive team with experience in GI therapeutics, commercialization, and biopharmaceutical operations. The leadership team emphasizes disciplined execution, regulatory rigor, and focused commercialization of differentiated therapies for underserved GI patient populations.
Key executives include:
- Terrie Curran – President and Chief Executive Officer
- Azmi Nabulsi, MD – Chief Medical Officer
- Christopher R. Shuey – Chief Financial Officer
- Steven Basta – Chief Operating Officer
- Mike Molnar – Chief Commercial Officer
The company is governed by a board of directors with backgrounds in pharmaceuticals, finance, and corporate governance, supporting its transition from a development-stage to a commercial-stage biopharmaceutical company.